Eli Lilly and Co (LLY) : Viking Global Investors Lp reduced its stake in Eli Lilly and Co by 20.29% during the most recent quarter end. The investment management company now holds a total of 9,377,395 shares of Eli Lilly and Co which is valued at $752,254,627 after selling 2,386,383 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Eli Lilly and Co makes up approximately 2.97% of Viking Global Investors Lp’s portfolio.
Other Hedge Funds, Including , Millennium Management boosted its stake in LLY in the latest quarter, The investment management firm added 536,342 additional shares and now holds a total of 892,391 shares of Eli Lilly and Co which is valued at $71,587,606. Eli Lilly and Co makes up approx 0.18% of Millennium Management’s portfolio.Baldwin Brothers Incma reduced its stake in LLY by selling 125 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 11,332 shares of LLY which is valued at $909,053. Eli Lilly and Co makes up approx 0.18% of Baldwin Brothers Incma’s portfolio.Ironbridge Capital Management Lp reduced its stake in LLY by selling 90 shares or 0.02% in the most recent quarter. The Hedge Fund company now holds 456,880 shares of LLY which is valued at $36,650,914. Eli Lilly and Co makes up approx 1.54% of Ironbridge Capital Management Lp’s portfolio.World Asset Management Inc boosted its stake in LLY in the latest quarter, The investment management firm added 802 additional shares and now holds a total of 97,091 shares of Eli Lilly and Co which is valued at $8,031,368. Eli Lilly and Co makes up approx 0.30% of World Asset Management Inc’s portfolio.Grandfield Dodd boosted its stake in LLY in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 7,761 shares of Eli Lilly and Co which is valued at $643,309. Eli Lilly and Co makes up approx 0.09% of Grandfield Dodd’s portfolio.
Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.